Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | DGKA | P23743 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30531672 | 0.88 | TSHR (0.43) | LMNAKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL4365179 | 0.85 | LMNA (0.48) | LMNAKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL29375450 | 0.83 | TSHR (0.61) | LMNAKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL9131960 | 0.83 | LMNA (0.44) | LMNAKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL16863053 | 0.83 | TSHR (0.61) | LMNAKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL25708 | 0.83 | LMNA (0.44) | LMNAKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL25707 | 0.83 | TSHR (0.61) | LMNAKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL12691690 | 0.82 | TSHR (0.39) | LMNAKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL29619673 | 0.81 | — | — | |
| SCHEMBL33457 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11946036-B2 | Bacterium and obtaining method and application thereof | SHANGHAI JIAO TONG UNIVERSITY (CN) | 2024-04-02 | — | — | US | claimed |
| US-20220162546-A1 | Bacterium And Obtaining Method And Application Thereof | SHANGHAI JIAO TONG UNIVERSITY (CN) | 2022-05-26 | — | — | US | claimed |
| CN-111991411-A | Application of composition in preparation of veterinary anthelmintic drug, transdermal anthelmintic solution for veterinary use and preparation method of transdermal anthelmintic solution | 吉林吉力生物技术研究有限公司 | 2020-11-27 | — | — | CN | claimed |
| CN-106190936-B | Bacterium and construction method and application thereof | 上海交通大学 | 2020-07-10 | — | — | CN | claimed |
| CN-106190901-B | Bacterium and obtaining method and application thereof | 上海交通大学 | 2020-06-26 | — | — | CN | claimed |
| US-20190218629-A1 | Bacterium And Obtaining Method And Application Thereof | SHANGHAI JIAO TONG UNIVERSITY (CN) | 2019-07-18 | — | — | US | claimed |
| US-5876916-A | ADMINISTRATION OF GLYCEROL-PYRUVATE OR HYDROXYACETONE PYRUVATE ESTER WITH BIOCOMPATIBLE CARRIER TO MAMMALS; AS HIGH CALORIE FOOD, ANTICHOLESTEROL AGENTS, ANTIISHEMIC AGENTS, ORGAN PRESERVATIVE, ANTIDIABETIC AGENTS | CASE WESTERN RESERVE UNIVERSITY (US) | 1999-03-02 | — | — | US | claimed |
| EP-0888267-A1 | NOVEL PYRUVATE COMPOUNDS AND METHODS FOR USE THEREOF | CASE WESTERN RESERVE UNIVERSITY (US) | 1999-01-07 | — | — | EP | claimed |
| WO-1997034856-A1 | NOVEL PYRUVATE COMPOUNDS AND METHODS FOR USE THEREOF | CASE WESTERN RESERVE UNIVERSITY (US) | 1997-09-25 | — | — | WO | claimed |
| JP-56148236-A | — | — | None | — | — | JP | disclosed |
| EP-4740750-A2 | PROCESSING AID FOR THE PREPARATION OF BAKERY PRODUCTS | Il Granaio delle Idee Srl (IT) | 2026-05-13 | — | — | EP | disclosed |
| US-12622967-B2 | Molecules, formulations, and methods for nutritional support of athletes, patients, and others | TODAY, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| EP-3772965-B1 | USE OF A PROCESSING AID FOR THE PREPARATION OF BAKERY PRODUCTS | IL GRANAIO DELLE IDEE SRL (IT) | 2026-02-18 | — | — | EP | disclosed |
| US-20240299548-A1 | MOLECULES, FORMULATIONS, AND METHODS FOR NUTRITIONAL SUPPORT OF ATHLETES, PATIENTS, AND OTHERS | TODAY, INC. (US) | 2024-09-12 | — | — | US | disclosed |
| EP-0888267-A1 | NOVEL PYRUVATE COMPOUNDS AND METHODS FOR USE THEREOF | CASE WESTERN RESERVE UNIVERSITY (US) | 1999-01-07 | — | — | EP | disclosed |
| WO-1998051277-A1 | MEDICAL USES OF PYRUVATES | CASE WESTERN RESERVE UNIVERSITY (US) | 1998-11-19 | — | — | WO | disclosed |
| WO-1997034856-A1 | NOVEL PYRUVATE COMPOUNDS AND METHODS FOR USE THEREOF | CASE WESTERN RESERVE UNIVERSITY (US) | 1997-09-25 | — | — | WO | disclosed |
| WO-1997034856-A1 | NOVEL PYRUVATE COMPOUNDS AND METHODS FOR USE THEREOF | CASE WESTERN RESERVE UNIVERSITY (US) | 1997-09-25 | — | — | WO | disclosed |
| US-5164069-A | PRINTED CIRCUITS | SHIPLEY COMPANY INC. (US) | 1992-11-17 | — | — | US | disclosed |
| JP-S56148236-A | KEEPING METHOD OF FRESHNESS OF BIRD EGG | RIKEN VITAMIN CO LTD | 1981-11-17 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622967-B2 | Molecules, formulations, and methods for nutritional support of athletes, patients, and others | SLC2A9, GYS1, SLC2A8 | LMNA 3333/4885KDM4E 1504/4885DUSP3 1156/4885 |
| US-20240299548-A1 | MOLECULES, FORMULATIONS, AND METHODS FOR NUTRITIONAL SUPPORT OF ATHLETES, PATIENTS, AND OTHERS | CPT1B, GK, CPT1A | LMNA 1973/4885KDM4E 3282/4885DUSP3 3193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.